ERBB2 and neoplasm: It was studied with CAPOX as a first-line treatment for CLDN18.2-positive (IHC1/2/3+ in ≥10% of tumor cells), HER2-negative, advanced/metastatic GAC/GEJ in a phase I/II trial [39,40].